Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie
- Address
- lock Available on a paid plan
Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie - Dermatology and Immunology Research Center
Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie serves as a leading academic medical center conducting advanced clinical research in dermatological and immunological conditions. The center demonstrates exceptional expertise in investigating novel therapeutic approaches for complex skin and autoimmune disorders, with particular emphasis on biologics and targeted therapies for inflammatory and autoimmune skin conditions.
- Autoimmune and Inflammatory Skin Diseases: comprehensive research in psoriasis (plaque, genital, palmoplantar pustulosis), hidradenitis suppurativa, atopic dermatitis, bullous pemphigoid, and prurigo nodularis
- Cutaneous Lupus Erythematosus: specialized investigations into subacute cutaneous lupus, chronic cutaneous lupus, and primary discoid lupus erythematosus treatment strategies
- Urticaria and Immune-Mediated Conditions: clinical trials in chronic spontaneous urticaria, chronic inducible urticaria, and alopecia areata with innovative immunomodulatory agents
- Emerging Dermatology Research: studies in acne vulgaris, actinic keratosis, vitiligo, and advanced topical therapies
The center's research portfolio showcases extensive experience with JAK inhibitors, IL-17 antagonists, IL-23 inhibitors, and other advanced biologic therapies. Through participation in Phase 2-4 clinical trials, the hospital contributes to developing breakthrough treatments for patients with moderate-to-severe dermatological conditions. The facility also maintains active research programs in nephrology and oncology, demonstrating its multidisciplinary approach to clinical investigation and commitment to advancing patient care through evidence-based medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 12 therapeutic areas and 15 of 81 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 80 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Incyte Corp.7trials
lock +20 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie
lock Showing 1 of 84 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis | Almirall S.A. | Phase III | Not Recruiting | May 2023 | Apr 2026 |
IMP list
lock Showing 1 of 81 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 5 | Unknown | 2025-04-01 | 2026-04-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.